Potential conflicts of interest. G. M.-K. reports funds awarded for the PANDA trial, paid to institution, from the Medical Research Future Fund; payments for travel from University of Wollongong and New South Wales Health; and unpaid leadership or fiduciary role with Australian Skeptics, Inc. J. S. F. reports payment for expert testimony from the Board of Medicine, Maine (author testified in a hearing about evidence-based practices related to COVID-19; author does not specifically remember whether Paxlovid was discussed, but in that context, author's testimony would have been that Paxlovid was found in at least 1 high-quality randomized placebo-controlled trial to be an important and effective treatment in preventing severe COVID-19 outcomes). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.